Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

1.7K
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.7K
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

4.0K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
4.0K
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

2.2K
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
2.2K
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

2.9K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
2.9K
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

2.5K
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
2.5K
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

591
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
591

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Level Up Your Residency: Can a Novel Two-Week Simulation Rotation Really Make a Difference?

Cureus·2024
Same author

Erroneous electrocardiographic interpretations and its clinical implications.

Journal of cardiovascular electrophysiology·2023
Same author

The Arrhythmogenicity of Sotalol and its Role in Heart Failure: A Literature Review.

Journal of cardiovascular pharmacology·2023
Same author

A case report of deglutition triggered atrial fibrillation in a patient with Laing distal myopathy.

European heart journal. Case reports·2021
Same author

Do ICD diagnostics predict failure of ventricular tachycardia response to antitachycardia pacing and need for shock?

Pacing and clinical electrophysiology : PACE·2020
Same author

Heart failure as a substrate and trigger for ventricular tachycardia.

Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing·2019

Related Experiment Video

Updated: Mar 18, 2026

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

11.1K

Ranolazine Therapy in Cardiac Arrhythmias.

Brian R Pulford1, Jeffrey Kluger2

  • 1Department of Medicine, University of Connecticut School of Medicine. bpulford@uchc.edu.

Pacing and Clinical Electrophysiology : PACE
|July 1, 2016
PubMed
Summary

Ranolazine, an antianginal drug, shows promise in treating atrial and ventricular arrhythmias, including post-CABG atrial fibrillation. Combination therapy may enhance its antiarrhythmic effects.

Keywords:
VTatrial fibrillationclinical trialsdata analysispharmacology

More Related Videos

Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus
08:28

Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus

Published on: April 5, 2011

18.3K
Rat Model of Right-Sided Cardiac Remodeling and Arrhythmia Using Pulmonary Artery Banding
10:39

Rat Model of Right-Sided Cardiac Remodeling and Arrhythmia Using Pulmonary Artery Banding

Published on: August 30, 2024

1.5K

Related Experiment Videos

Last Updated: Mar 18, 2026

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

11.1K
Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus
08:28

Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus

Published on: April 5, 2011

18.3K
Rat Model of Right-Sided Cardiac Remodeling and Arrhythmia Using Pulmonary Artery Banding
10:39

Rat Model of Right-Sided Cardiac Remodeling and Arrhythmia Using Pulmonary Artery Banding

Published on: August 30, 2024

1.5K

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Ranolazine, approved in 2006, is an antianginal medication.
  • Clinical evidence suggests ranolazine's efficacy in preventing and treating atrial and ventricular arrhythmias.
  • Postoperative atrial fibrillation after coronary artery bypass graft (CABG) surgery is a key indication.

Purpose of the Study:

  • To review ranolazine's pharmacology and antiarrhythmic applications.
  • To examine studies on ranolazine for atrial and ventricular arrhythmias.
  • To explore combination therapy for enhanced arrhythmia suppression.

Main Methods:

  • Review of existing clinical trials and case reports on ranolazine.
  • Analysis of pharmacological data related to ranolazine's mechanism of action.
  • Investigation of studies combining ranolazine with other antiarrhythmic agents.

Main Results:

  • Ranolazine demonstrates potential in managing various arrhythmias.
  • Studies indicate effectiveness in preventing and treating atrial fibrillation post-CABG.
  • Initial research suggests synergistic effects when combined with dronedarone for atrial fibrillation.

Conclusions:

  • Ranolazine is a viable option for specific arrhythmia management.
  • Further research is warranted to fully understand its antiarrhythmic potential and combination therapies.
  • Combination of dronedarone with ranolazine shows promise for atrial fibrillation treatment.